Year-end Sale % OFF 
Abstract
Background: A large number of studies have reported the aberrant expression of special AT-rich sequence binding protein 1 (SATB1) in colorectal cancer (CRC). However, the role of SATB1 in CRC is still controversial. Therefore, we performed this meta-analysis to elucidate the prognostic and clinical value of SATB1 in CRC patients.Methods: We searched Web of Science, EMBASE and PubMed entirely in January 2018 to identify related articles. Pooled Hazard ratio (HR) was adopted to evaluate the prognostic value of SATB1 in CRC and odd ratio (OR) was used to assess the clinicopathological significance of SATB1 in CRC.Results: Ten eligible studies containing 7 on prognosis and 9 on clinicopathological characteristics were finally included in the present meta-analysis. Results revealed that patients with high expression of SATB1 tended to have shorter overall survival (OS) (pooled HR: 1.64, 95% CI: 1.04–2.57). Besides, we also discovered that the expression of SATB1 was associated with histologic grade (OR = 1.88, 95% CI: 1.06–3.34), distant metastasis (OR = 1.43, 95% CI: 1.11–1.85) and lymph node metastasis (OR = 1.50, 95% CI: 1.03–2.19).Conclusion: Broadly speaking, our meta-analysis demonstrated that high expression level of SATB1 was related to poor prognosis in CRC patients.
Highlights
Colorectal cancer (CRC) is reported to be one of the primary health threats to mankind worldwide accounting for the second most common cancer in women and third in men (Siegel et al, 2014)
Results revealed that patients with high expression of SATB1 tended to have shorter overall survival (OS)
Broadly speaking, our meta-analysis demonstrated that high expression level of SATB1 was related to poor prognosis in CRC patients
Summary
Colorectal cancer (CRC) is reported to be one of the primary health threats to mankind worldwide accounting for the second most common cancer in women and third in men (Siegel et al, 2014). Huge efforts have been made by studies to identify new and powerful biomarkers that could early detect or accurately predict the prognosis of patients with CRC (Rodia et al, 2017). A large number of studies have reported the aberrant expression of special AT-rich sequence binding protein 1 (SATB1) in colorectal cancer (CRC). The role of SATB1 in CRC is still controversial. We performed this meta-analysis to elucidate the prognostic and clinical value of SATB1 in CRC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
